FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, medicine and veterinary medicine, namely oncology, the development of submersible medical devices for personalized therapy, in particular for local cytoreductive therapy of patients with solid tumors by paratumoral implantation of the product. A biodegradable implant for local immunotherapy of cancer patients is a scaffold made of a biodegradable alloy based on iron and manganese, made in the form of a plate with oblong slits forming reservoirs for the active composition filled with a cell-mobilizing medium based on hydrogel and a biomedical cell product based on autologous or allogeneic T-lymphocytes and natural killers activated ex vivo.
EFFECT: invention provides targeted transportation and long-term survival of cells deposited in the hydrogel in the area of administration, as well as the implementation of prolonged local cytotoxic effects of effector cells on tumor cells by direct cytotoxic effects, as well as activation of specific and non-specific links of the patient’s immunity.
1 cl, 2 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
BIODEGRADABLE METAL IMPLANT FOR LOCAL IMMUNOTHERAPY OF PATIENTS WITH SOLID TUMORS | 2021 |
|
RU2780927C1 |
TITANIUM IMPLANT WITH THE FUNCTION OF LOCAL IMMUNOTHERAPY FOR OSTEORECONSTRUCTIVE SURGERY AND PREVENTION OF LOCAL RECURRENCE OF ONCOLOGICAL DISEASE AND METHOD FOR ITS MANUFACTURE | 2021 |
|
RU2779367C1 |
SUBCUTANEOUS BIODEGRADABLE IMPLANT FOR DELAYED HEMOSTIMULATION OF CANCER PATIENTS | 2023 |
|
RU2809091C1 |
BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
CELL PRODUCT FOR LOADING AND ACTIVATION OF HUMAN DENDRITE CELLS | 2019 |
|
RU2714208C1 |
BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
METHOD FOR TARGETED DELIVERY OF THERAPEUTIC DRUGS TO TUMOR CELLS | 2022 |
|
RU2789807C1 |
METHOD OF IMMUNOTHERAPY WITH BONE-MARROW PRECURSORS OF DENDRITE CELLS, SENSIBILISED WITH PHOTOMODIFIED TUMOR CELLS IN VIVO, FOR PATIENTS DISSEMINATED WITH SOLID TUMORS | 2008 |
|
RU2376033C1 |
IMMUNOTHERAPY METHOD FOR TREATING PATIENTS FOR SOLID TUMORS BY APPLYING TUMOR LYSATE WITH BETALEUKINE ADJUVANT | 2004 |
|
RU2267326C2 |
Authors
Dates
2022-10-04—Published
2021-11-25—Filed